Corrigendum to: The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms (American Journal of Hematology, (2023), 98, 1, (166-179), 10.1002/ajh.26751)

Corrigendum In Ref. [1], Table 4 at page 6 entitled Diagnostic criteria for Polycythemia Vera (PV) and post-polycythemic myelofibrosis (post-PV MF) slightly modified and adapted, the left column entitled PV shows an incorrect major criteria numbering. Major criterion “2” was switched with “3.” The corresponding footnotes “b” and “c” were also switched. Because bone marrow biopsy is now moved to “2” the last sentence of footnote “c” is no longer needed and has been removed. Corrected Table 4 is shown below: The authors apologize for the error. 4 TABLE Diagnostic criteria for Polycythemia Vera (PV) and post-polycythemic myelofibrosis (post-PV MF) slightly modified and adapted^2,4 (Table presented.) The diagnosis of PV requires either all three major criteria or the first two major criteria plus the minor criterion. The diagnosis of post-PV MF is established by all required criteria and at least two additional criteria. a) Diagnostic thresholds: hemoglobin: >16.5 g/dL in men and >16.0 g/dL in women, hematocrit: >49% in men and >48% in women, red blood cell mass: >25% above mean normal predicted value. b) A bone marrow biopsy may not be required in patients with sustained absolute erythrocytosis (hemoglobin concentrations of >18.5 g/dL in men or >16.5 g/dL in women and hematocrit values of >55.5% in men or >49.5% in women) and the presence of a JAK2 V617F or JAK2 exon 12 mutation. However, initial MF (present in as many as 20% of patients) can only be detected by BM, and this finding may predict a more rapid progression to overt myelofibrosis (post-PV myelofibrosis).⁶⁷ c) It is recommended to use highly sensitive assays for JAK2 V617F (sensitivity level <1%) and CALR and MPL (sensitivity level 1%–3%)—in negative cases, consider searching for non-canonical or JAK2 mutations.